SSY Group (HKG:2005) obtained production and registration approval for Cefpodoxime Proxetil for Suspension from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The move came after the drug was regarded as passing the regulator's consistency evaluation, the pharmaceutical company said.
The drug is used to treat infections caused by susceptible bacteria, including upper and lower respiratory tract, uncomplicated urinary tract, and uncomplicated skin and soft tissue infections.
The drug also treats acute uncomplicated gonococcal urethritis and cervicitis, as well as perianal inflammation caused by Neisseria gonorrhoea.